Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MTNB Stock Forecast 2025-2026
$0.89
Current Price
$5.73M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to MTNB Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
MTNB Price Momentum
+9.9%
1 Week Change
-30.5%
1 Month Change
+45.9%
1 Year Change
+74.5%
Year-to-Date Change
-71.1%
From 52W High of $3.09
+88.3%
From 52W Low of $0.47
📊 TOP ANALYST CALLS
Did MTNB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Matinas is one of their latest high-conviction picks.
Latest MTNB Stock Price Targets & Analyst Predictions
MTNB has shown a year-to-date change of 74.5% and a 1-year change of 45.9%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for MTNB. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MTNB Analyst Ratings
0
Buy
1
Hold
0
Sell
MTNB Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.89
Latest MTNB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MTNB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 31, 2024 | Maxim Group | Jason McCarthy | Hold | Downgrade | $N/A |
| Oct 11, 2023 | BTIG | Julian Harrison | Buy | Reinstates | $3.00 |
| Jan 31, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $3.00 |
| Aug 13, 2020 | Aegis Capital | Buy | Maintains | $3.50 | |
| Jan 27, 2020 | Piper Sandler | Overweight | Initiates | $N/A | |
| Jan 24, 2020 | SunTrust Robinson Humphrey | Buy | Initiates | $N/A | |
| Jun 26, 2019 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Jun 26, 2019 | H.C. Wainwright | Buy | Initiates | $N/A | |
| May 17, 2019 | BTIG | Buy | Initiates | $N/A | |
| May 17, 2019 | BTIG Research | Buy | Initiates | $N/A | |
| Feb 11, 2019 | Roth Capital | Buy | Initiates | $N/A | |
| Nov 13, 2018 | Maxim Group | Jason McCarthy | Buy | Maintains | $5.00 |
| Aug 13, 2018 | Maxim Group | Jason McCarthy | Buy | Maintains | $2.00 |
| Jul 10, 2018 | Maxim Group | Jason McCarthy | Buy | Maintains | $3.00 |
| Nov 1, 2016 | Aegis Capital | Buy | Initiates | $N/A |
Matinas Biopharma Holdings Inc. (MTNB) Competitors
The following stocks are similar to Matinas based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Matinas Biopharma Holdings Inc. (MTNB) Financial Data
Matinas Biopharma Holdings Inc. has a market capitalization of $5.73M with a P/E ratio of -0.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -151.7%.
Valuation Metrics
Market Cap
$5.73M
Enterprise Value
$1.96M
P/E Ratio
-0.2x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+94.8%
Current Ratio
3.8x
Debt/Equity
36.1x
ROE
-151.7%
ROA
-38.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Matinas Biopharma Holdings Inc. (MTNB) Business Model
About Matinas Biopharma Holdings Inc.
What They Do
Develops novel therapeutics using lipid nano-crystal technology.
Business Model
Matinas Biopharma Holdings Inc. operates as a clinical-stage biopharmaceutical company focusing on innovative drug delivery systems. The company generates revenue by advancing its proprietary lipid nano-crystal technology to improve the bioavailability and efficacy of pharmaceuticals, particularly for infectious diseases and rare disorders. This strategic approach not only addresses unmet medical needs but also positions the company to capitalize on the growing demand for enhanced drug delivery solutions.
Additional Information
Matinas Biopharma is dedicated to transforming the treatment landscape through its advanced delivery platforms, which aim to optimize drug exposure and safety profiles. By enabling oral dosing of complex molecules, the company seeks to improve patient outcomes and quality of life, making it a significant player in the biotechnology sector with potential impacts on the healthcare and pharmaceutical industries.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
3
CEO
Mr. Jerome D. Jabbour J.D.
Country
United States
IPO Year
2014
Website
www.matinasbiopharma.comMatinas Biopharma Holdings Inc. (MTNB) Latest News & Analysis
Latest News
Quick Summary
Matinas BioPharma appointed Keith Murphy and Edward Neugeboren as independent board members, effective March 11, 2025.
Why It Matters
The appointment of seasoned biotech professionals to Matinas BioPharma's board signals potential strategic growth and enhanced credibility, which could positively influence investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma Holdings, Inc. announced a securities purchase agreement to sell 3,300 shares of Series C Convertible Preferred Stock and warrants for $3.3 million in gross proceeds.
Why It Matters
Matinas BioPharma's $3.3 million capital raise through preferred stock and warrants signals investor confidence and could enhance liquidity for growth initiatives.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma appointed Evelyn D'An as an independent director and Chair of the Audit Committee, effective February 5, 2025.
Why It Matters
Evelyn D'An's appointment to Matinas BioPharma's Board could enhance governance and financial oversight, potentially boosting investor confidence and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Matinas BioPharma Receives NYSE Noncompliance Notice
10 months ago
Quick Summary
Matinas BioPharma Holdings, Inc. (MTNB) received a notice from NYSE American for failing to meet listing standards due to not holding its annual stockholders meeting for FY 2024.
Why It Matters
Matinas BioPharma's failure to hold its annual meeting may signal governance issues, potentially affecting investor confidence and the stock's market performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma has terminated negotiations for global rights to MAT2203, resulting in an 80% workforce reduction and cessation of product development to conserve cash.
Why It Matters
The termination of negotiations and workforce reduction signal financial distress for Matinas BioPharma, likely leading to decreased investor confidence and potential stock price declines.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma Holdings, Inc. (NYSE:MTNB) will host its Q2 2024 earnings conference call on August 14, 2024, at 4:30 PM ET, featuring key company executives and analysts.
Why It Matters
The earnings conference call provides insights into Matinas BioPharma's financial performance and future strategies, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About MTNB Stock
What is Matinas Biopharma Holdings Inc.'s (MTNB) stock forecast for 2026?
Analyst forecasts for Matinas Biopharma Holdings Inc. (MTNB) are not currently available. The stock is trading at $0.89.
Is MTNB stock a good investment in 2026?
According to current analyst ratings, MTNB has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.89. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MTNB stock?
Price predictions from Wall Street analysts for MTNB are not currently available. The stock is trading at $0.89.
What is Matinas Biopharma Holdings Inc.'s business model?
Matinas Biopharma Holdings Inc. operates as a clinical-stage biopharmaceutical company focusing on innovative drug delivery systems. The company generates revenue by advancing its proprietary lipid nano-crystal technology to improve the bioavailability and efficacy of pharmaceuticals, particularly for infectious diseases and rare disorders. This strategic approach not only addresses unmet medical needs but also positions the company to capitalize on the growing demand for enhanced drug delivery solutions.
What is the highest forecasted price for MTNB Matinas Biopharma Holdings Inc.?
Price targets from Wall Street analysts for MTNB are not currently available. The stock is trading at $0.89.
What is the lowest forecasted price for MTNB Matinas Biopharma Holdings Inc.?
Price targets from Wall Street analysts for MTNB are not currently available. The stock is trading at $0.89.
What is the overall MTNB consensus from analysts for Matinas Biopharma Holdings Inc.?
The overall analyst consensus for MTNB is neutral. Out of 4 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are MTNB stock price projections?
Stock price projections, including those for Matinas Biopharma Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 9, 2025 5:21 AM UTC